PL3720442T3 - Hamowanie mutanta idh-1 - Google Patents

Hamowanie mutanta idh-1

Info

Publication number
PL3720442T3
PL3720442T3 PL19728271.8T PL19728271T PL3720442T3 PL 3720442 T3 PL3720442 T3 PL 3720442T3 PL 19728271 T PL19728271 T PL 19728271T PL 3720442 T3 PL3720442 T3 PL 3720442T3
Authority
PL
Poland
Prior art keywords
idh
mutant
inhibition
Prior art date
Application number
PL19728271.8T
Other languages
English (en)
Inventor
Patrick F. Kelly
Alan Collis
Jeff Davis
Duncan Walker
Susan Ashwell
Blythe THOMSON
Lu WEI
Original Assignee
Forma Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics, Inc. filed Critical Forma Therapeutics, Inc.
Priority claimed from PCT/US2019/032747 external-priority patent/WO2019222553A1/en
Publication of PL3720442T3 publication Critical patent/PL3720442T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PL19728271.8T 2018-05-16 2019-05-16 Hamowanie mutanta idh-1 PL3720442T3 (pl)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201862672461P 2018-05-16 2018-05-16
US201862672462P 2018-05-16 2018-05-16
US201862680566P 2018-06-04 2018-06-04
US201862680571P 2018-06-04 2018-06-04
US201862680560P 2018-06-04 2018-06-04
US201862680562P 2018-06-04 2018-06-04
US201862692604P 2018-06-29 2018-06-29
US201862692591P 2018-06-29 2018-06-29
US201862692601P 2018-06-29 2018-06-29
US201862692598P 2018-06-29 2018-06-29
US201862692605P 2018-06-29 2018-06-29
US201862773562P 2018-11-30 2018-11-30
US201962798687P 2019-01-30 2019-01-30
US201962798677P 2019-01-30 2019-01-30
US201962798681P 2019-01-30 2019-01-30
US201962798690P 2019-01-30 2019-01-30
US201962798684P 2019-01-30 2019-01-30
US201962812367P 2019-03-01 2019-03-01
PCT/US2019/032747 WO2019222553A1 (en) 2018-05-16 2019-05-16 Inhibiting mutant idh-1

Publications (1)

Publication Number Publication Date
PL3720442T3 true PL3720442T3 (pl) 2023-05-29

Family

ID=85705783

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19728271.8T PL3720442T3 (pl) 2018-05-16 2019-05-16 Hamowanie mutanta idh-1

Country Status (12)

Country Link
US (1) US20260060975A1 (pl)
EP (1) EP4215197A1 (pl)
DK (1) DK3720442T3 (pl)
ES (1) ES2941079T3 (pl)
FI (1) FI3720442T3 (pl)
HR (1) HRP20230168T1 (pl)
LT (1) LT3720442T (pl)
MD (1) MD3720442T2 (pl)
PL (1) PL3720442T3 (pl)
RS (1) RS64069B1 (pl)
SI (1) SI3720442T1 (pl)
SM (1) SMT202300073T1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
MA53352A (fr) 2014-09-19 2021-09-15 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
AU2015317327B9 (en) 2014-09-19 2020-04-09 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors

Also Published As

Publication number Publication date
FI3720442T3 (fi) 2023-03-17
HRP20230168T1 (hr) 2023-05-12
LT3720442T (lt) 2023-04-25
EP4215197A1 (en) 2023-07-26
MD3720442T2 (ro) 2023-09-30
DK3720442T3 (da) 2023-03-27
SMT202300073T1 (it) 2023-05-12
US20260060975A1 (en) 2026-03-05
RS64069B1 (sr) 2023-04-28
ES2941079T3 (es) 2023-05-16
SI3720442T1 (sl) 2023-06-30

Similar Documents

Publication Publication Date Title
MA52739A (fr) Endonucléases cpf1 mutantes
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
EP3824778A4 (en) Shower head
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3745005A4 (en) FITTING
EP3870179A4 (en) USP7 ESCAPEMENT
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
IL284374A (en) Methods of producing ustekinumab
DOS2019000134S (es) Ornamentacion
DOS2019000137S (es) Ornamentación
EP3738603A4 (en) NTCP INHIBITOR
DOS2019000133S (es) Ornamentación
DOS2019000135S (es) Ornamentación
DOS2019000136S (es) Ornamentacion
DOS2019000138S (es) Ornamentacion
ES1225190Y (es) Conjunto de ducha
IL276107A (en) Crystalline forms of psoorstam
DK3899336T3 (da) Vvs-armatur
DOS2019000161S (es) Ornamentación
IL281409A (en) Musk inhibition
EP3962486A4 (en) ESCAPEMENT OF USP36
EP3996650C0 (en) BATHTUB
EP3936017A4 (en) Bathtub
PL3720442T3 (pl) Hamowanie mutanta idh-1
SG11202101817UA (en) Methods of inhibition